重组干扰素α-2a,α-2b治疗慢性乙型肝炎疗效比较  

The therapeutic efficacy of recombinant interferon alfa - 2a and alfa - 2b for the treatment of chronic hepatitis B

作　　者：武宗导[1] 王功大[1] 许洁 邢国珍 

机构地区：[1]上海第二医科大学附属宝钢医院传染科,上海201900

出　　处：《临床肝胆病杂志》2003年第2期90-91,共2页Journal of Clinical Hepatology

摘　　要：探讨不同亚型α干扰素(IFNα-2a、IFNα-2b)治疗慢性乙型肝炎的疗效差异。110例慢性乙型肝炎(CHB)患者被随机分为IFNα-2a治疗组(52例)和IFNα-2b治疗组(58例)。IFNα-2a治疗组采用IFNα-2a(因特芬)每日3MU肌注,IFNα-2b治疗组采用IFNα-2b(隆化诺)每日3MU肌注,30天后改隔日3MU肌注,疗程6月。观察两组用药3月、6月后血清ALT复常率、HBeAg阴转率、HBV-DNA阴转率和治疗反应率。ALT复常率两组无明显差异(P>0.05)。HBeAg阴转率:IFNα-2b治疗组(51.7％、67.2％),明显优于IFNα-2a治疗组(32.7％、44.2％),两组差异明显(P<0.05)。HBV DNA阴转率:6月后IFNα-2b治疗组(58.6％),明显优于IFNα-2a治疗组(34.6％),两组差异明显(P<0.05)。治疗后完全反应率:IFNα-2b治疗组(46.6％),明显优于IFNα-2a治疗组(21.2％),两组间有极显著差异(P<0.01)。干扰素α-2b亚型治疗慢性乙型肝炎疗效明显优于干扰素α-2a亚型。To study the therapeutic efficacy of recombinant interferon alfa - 2a and alfa - 2b for the treatment of chronic hepatitis B 110 Chinese patients with chronic hepatitis B entered randomly into two groups. One group (52) was given IFNα- 2a 3 million u-nit(MU)/day. The control group (58) was given IFNa- 2b 3 million (3MU)/day. The changes of ALT, HBeAg and HBV DNA in the serum were observed and analyzed after three and six months later. On removing of HBeAg, The IFNa - 2b therapy group was(51.7% ,67.2% ) and the IFNα - 2a therapy group was (32.7% ,44.2%). On removing of HBV DNA, The IFNα - 2b therapy group was (58.6%) and the IFNα-2a therapy group was (34.6%) after 6 months later. The IFNα-2b therapy group efficacy was higher than The IFNα - 2a therapy group (P < 0.05). The end treatment response of both HBeAg and HBV DNA, the IFNα-2b therapy group was (46.6%) and the IFNα- 2a therapy group was (21.2%). there was a significant difference between two groups ( P < 0.01). The therapeutic efficacy of recombinant interferon alfa - 2b was better than the IFNα - 2a for the treatment of chronic hepatitis B.

关 键 词：重组 干扰系α-2α 干扰素Α-2B 慢性乙型肝炎 抗病毒 

分 类 号：R512.62[医药卫生—内科学]